CTLA4 and sarcoma: In support of this observation, longitudinal sampling of murine sarcoma treated with anti-PD-1/anti-CTLA-4 suggested that macrophage activation following ICB was due to effects on circulating monocytes and early macrophages entering tumours, rather than mature intratumoural macrophages (74).